PeterSguignaMD

PubMed

• Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clin...
  Ren, J., Dewey, R., Rynders, A., Evan, J., Evan, J., Ligozio, S., Ho, K., Glanzman, R., Hotchkin, M., Dewey, R., Sguigna, P., Greenberg, B.> ;Journal of Nanobiotechnology. 2024 Jan 3
• Cladribine tablets after treatment with natalizumab (CLADRINA) - rationale and design.
  Rehana Z Hussain, Mariam Madinawala, Julie Korich, Lori A Lebson, Amber Salter, Navid Manouchehri, Peter V Sguigna, Annette Okai, Kyle M Blackburn, Lauren Tardo, Jeffr...> ;Therapeutic Advances in Neurological Disorders. 2024 Jan 1
• 3 citations
  Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials.
  Ren, J., Dewey, R., Rynders, A., Evan, J., Evan, J., Ligozio, S., Ho, K., Glanzman, R., Hotchkin, M., Dewey, R., Sguigna, P., Greenberg, B.> ;Journal of Nanobiotechnology. 2023 Dec 13
• 1 citations
  Subclinical optic neuritis in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.
  Linda Nguyen, Cynthia X Wang, Darrel L Conger, Peter V Sguigna, Sumit Singh, Benjamin M Greenberg> ;Multiple Sclerosis and Related Disorders. 2023 Aug 1
• 1 citations
  Disease associations of excessive daytime sleepiness in multiple sclerosis: A prospective study.
  Peter V Sguigna, Sabeen Toranian, Lauren M Tardo, Kyle M Blackburn, Lindsay A Horton, Darrel Conger, Ethan Meltzer, R Nick Hogan, Morgan C McCreary, Phyllis C Zee, Jos...> ;Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2023 Mar 15
• A narrative review of neuro-ophthalmologic disease in African Americans and Hispanics with multiple sclerosis.
  Lauren Tardo, Amber Salter, Melanie Truong-Le, Lindsay Horton, Kyle M Blackburn, Peter V Sguigna> ;Therapeutic Advances in Chronic Disease. 2023 Jan 1
• 2 citations
  A cross-sectional natural history study of aspartylglucosaminuria.
  Kimberly Goodspeed, Daniel Horton, Andrea Lowden, Peter V Sguigna, Timothy Booth, Zhiyue J Wang, Veronica Bordes Edgar> ;JIMD Reports. 2022 Sep 1
• 1 citations
  Application of the International Interocular Difference Thresholds into Practice: Localising the Patient Experience.
  Peter V Sguigna, Lauren M Tardo, Kyle M Blackburn, Lindsay A Horton, Darrel L Conger, R Nick Hogan, Morgan C McCreary, Benjamin M Greenberg> ;Neuro-Ophthalmology. 2022 Jan 1
• The sequential natalizumab - alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial - Part I: Rationale and objectives.
  Rehana Z Hussain, Peter V Sguigna, Annette Okai, Crystal Wright, Mariam Madinawala, Ann D Bass, Gary R Cutter, Navid Manouchehri, Olaf Stuve> ;Journal of Central Nervous System Disease. 2022 Jan 1
• 1 citations
  Asymptomatic retinal vasculopathy in neuropsychiatric systemic lupus erythematosus.
  Peter Sguigna, Lauren Tardo, Darrel Conger, Robert N Hogan, Benjamin Greenberg> ;Journal of the Neurological Sciences. 2021 Aug 27
• 4 citations
  Utilization of Visual Acuity Retroilluminated Charts for the Assessment of Afferent Visual System Dysfunction in a Pediatric Neuroimmunology Population.
  Peter V Sguigna, Morgan C McCreary, Darrel L Conger, Jennifer Graves, Leslie Benson, Amy Waldman, Benjamin Greenberg> ;Journal of Neuro-Ophthalmology. 2021 Mar 1
• 1 citations
  Utilization of video oculography to quantify oculomotor dysfunction in anti-DPPX encephalitis: A case study
  Kyle M. Blackburn, Steven Vernino, Peter Sguigna> ;Multiple Sclerosis and Related Disorders. 2020 Aug 29
• Cataclysmically disseminating neurologic presentation in an immunosuppressed lupus patient: From the National Multiple Sclerosis Society Case Conference Proceedings.
  Christopher Perrone, Robert P. Lisak, Ethan Meltzer, Peter Sguigna, Etsegenet F. Tizazu, Dina A. Jacobs, Esther Melamed, Ashlea Lucas, Leorah Freeman, Gabriel Pardo, A...> ;Neurology(R) Neuroimmunology & Neuroinflammation. 2019 Jul 1
• 41 citations
  Atypical Anti-MOG syndrome with aseptic meningoencephalitis and pseudotumor cerebri-like presentations
  Ram Narayan, Cynthia Wang, Peter Sguigna, Khalil Husari, Benjamin Greenberg> ;Multiple Sclerosis and Related Disorders. 2019 Jan 1
• 21 citations
  Retinal Architecture and Melanopsin-Mediated Pupillary Response Characteristics: A Putative Pathophysiologic Signature for the Retino-Hypothalamic Tract in Multiple Sc...
  Ethan Meltzer, Peter Sguigna, Adnan Subei, Shin C. Beh, Eric J. Kildebeck, Darrel Conger, Amy Conger, Marlen Lucero, Benjamin S. Frohman, Ashley N. Frohman, Shiv Saidh...> ;JAMA Neurology. 2017 May 1
• 6 citations
  Managing Disability in Progressive Multiple Sclerosis.
  Divyanshu Dubey, Peter Sguigna, Olaf Stüve> ;Current Treatment Options in Neurology. 2016 Apr 19
• 4 citations
  Acute relapse after initiation of Siponimod in a patient with secondary progressive MS.
  Rehana Z. Hussain, Shirley O’Leary, Fides M. Pacheco, Tresa Zacharias, Paul Litvak, Peter Sguigna, Ellen Marder, Kevin F. Kia, Karanjit S. Kooner, Olaf Stüve> ;Journal of Neurology. 2016 Feb 25
• 121 citations
  Sterol-induced degradation of HMG CoA reductase depends on interplay of two Insigs and two ubiquitin ligases, gp78 and Trc8
  Youngah Jo, Peter C.W. Lee, Peter Sguigna, Russell A. DeBose-Boyd> ;Proceedings of the National Academy of Sciences of the United States of America. 2011 Dec 20
• 68 citations
  Membrane-associated Ubiquitin Ligase Complex Containing gp78 Mediates Sterol-accelerated Degradation of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase
  Youngah Jo, Peter Sguigna, Russell A. DeBose-Boyd> ;The Journal of Biological Chemistry. 2011 Apr 29
• Join now to see all